title: New drugs in non-Hodgkin's lymphoma.
abstract: While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the main-stay of therapy. Several new chemotherapy agents, including purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors, are discussed. Other issues important in lymphoma drug development, including the limited patient population available for evaluation of investigational agents, are also considered.
authors.affiliation: Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
authors.forename: S G
authors.initials: SG
authors.lastname: Arbuck
authors.forename: J M
authors.initials: JM
authors.lastname: Sorensen
authors.forename: M C
authors.initials: MC
authors.lastname: Christian
authors.forename: P
authors.initials: P
authors.lastname: Ho
authors.forename: J M
authors.initials: JM
authors.lastname: Pluda
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D054713:Bryostatins; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D018942:Macrolides; D013498:Suramin / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D054713:Bryostatins; D004791:Enzyme Inhibitors; D007783:Lactones; D018942:Macrolides; D059004:Topoisomerase I Inhibitors; C046785:bryostatin 1; D013498:Suramin; D000241:Adenosine